PITTSBURGH, March 22, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary UDL Laboratories, part of the Mylan Institutional business, has entered a license agreement with Humeca, a leading plastic surgery and burn treatment products company, for the exclusive U.S. distribution rights of Humeca products. Humeca, which is based in the Netherlands, has a portfolio that includes products used by burn, plastic and reconstructive surgeons to repair skin defects.
Mylan Institutional President Matt Erick commented: "Mylan Institutional is extremely pleased to have found a partner as strong as Humeca to accelerate our growth in the burn and wound care space. For the first time in the U.S., plastic and reconstructive surgeons will have access to Humeca's modified MEEK micrografting system, the method of choice for skin transplantation. The addition of Humeca's innovative products to UDL's established line of advanced wound and burn care products positions Mylan Institutional for growth in this sector."
Humeca's modified MEEK micrografting system greatly reduces the donor surface area required for skin transplantation when compared to the commonly-used mesh graft technique. This is especially useful for treating patients with large burns who have limited donor tissue availability.
UDL Laboratories is part of Mylan Institutional, a platform that provides differentiated pharmaceutical products to institutional customers throughout North America. Mylan Institutional's product offering includes the specialty injectables of Bioniche Pharma with the unit dose capabilities of Mylan's UDL Laboratories. Mylan Institutional's customers include group purchasing organizations, wholesalers, hospitals, surgical and radiology services, home infusion service providers, long-term care facilities, correctional facilities, specialty pharmacies, veterinary clinics and retail outlets.
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com.
SOURCE Mylan Inc.